Search or choose
Find the right test or package.
BCR-ABL Kinase Domain Mutations by PCR
The Imatinib resistance mutation analysis or BCR-ABL1 kinase domain mutation test by PCR is a molecular diagnostic test used to identify specific mutations within the BCR-ABL1 fusion gene associated with resistance to imatinib, a tyrosine kinase inhibitor used...
DiagnosticsLab test
Know more about this test
The Imatinib resistance mutation analysis or BCR-ABL1 kinase domain mutation test by PCR is a molecular diagnostic test used to identify specific mutations within the BCR-ABL1 fusion gene associated with resistance to imatinib, a tyrosine kinase inhi...
Understanding BCR-ABL Kinase Domain Mutations by PCR
The Imatinib resistance mutation analysis or BCR-ABL1 kinase domain mutation test by PCR is a molecular diagnostic test used to identify specific mutations within the BCR-ABL1 fusion gene associated with resistance to imatinib, a tyrosine kinase inhibitor used in chronic myeloid leukemia (CML) treatment. The test utilizes PCR to amplify and detect mutations in the kinase domain of the BCR-ABL1 gene. Identifying these mutations helps guide treatment decisions, allowing for alternative therapeutic strategies or the u...
What does BCR-ABL Kinase Domain Mutations by PCR measure?
The Imatinib resistance mutation analysis or BCR-ABL1 kinase domain mutation test by PCR is a molecular diagnostic test used to identify specific mutations within the BCR-ABL1 fusion gene associated with resistance to imatinib, a tyrosine kinase inhibitor used in chronic myeloid leukemia (CML) treatment. The test utilizes PCR to amplify and detect mutations in the kinase domain of the BCR-ABL1 gene. Identifying these mutations helps guide treatment decisions, allowing for alternative therapeutic strategies or the u...
Related parameters
How does home sample collection work?
Select slot
Pick a convenient time.
Phlebotomist visit
A trained expert arrives home.
Safe testing
Samples move through the lab process.
Digital reports
Reports are delivered online.